{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:26:12Z","timestamp":1789259172650,"version":"build-2803163510"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1499,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1111\/j.1369-1600.2011.00349.x","type":"journal-article","created":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T14:30:12Z","timestamp":1311690612000},"page":"709-716","source":"Crossref","is-referenced-by-count":85,"title":["<i>CYP2B6<\/i>SNPs are associated with methadone dose required for effective treatment of opioid addiction"],"prefix":"10.1111","volume":"18","author":[{"given":"Orna","family":"Levran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat","family":"Peles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Randesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Adelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jeanne","family":"Kreek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7,25]]},"reference":[{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1300\/J069v26n01_03","article-title":"Correlation between high methadone doses and methadone serum levels in methadone maintenance treatment (MMT) patients","volume":"26","author":"Adelson","year":"2007","journal-title":"J Addict Dis"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajhg.2010.04.015","article-title":"Abraham's children in the genome era: major Jewish diaspora populations comprise distinct genetic clusters with shared Middle Eastern Ancestry","volume":"86","author":"Atzmon","year":"2010","journal-title":"Am J Hum Genet"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nature09103","article-title":"The genome-wide structure of the Jewish people","volume":"466","author":"Behar","year":"2010","journal-title":"Nature"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1556-4029.2009.01278.x","article-title":"Postmortem blood concentrations of R- and S-enantiomers of methadone and EDDP in drug users: influence of co-medication and p-glycoprotein genotype","volume":"55","author":"Buchard","year":"2010","journal-title":"J Forensic Sci"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/clpt.2010.127","article-title":"OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths","volume":"88","author":"Bunten","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-200102000-00001","article-title":"Methadone maintenance treatment: is it possible to adapt the daily doses to the metabolic activity of the patient?","volume":"23","author":"Charlier","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clpt.2006.09.012","article-title":"ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment","volume":"80","author":"Crettol","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment","volume":"78","author":"Crettol","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2217\/14622416.8.3.293","article-title":"Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System","volume":"8","author":"Dumaual","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers","volume":"81","author":"Eap","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2125.1999.00921.x","article-title":"Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4","volume":"47","author":"Foster","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2125.2000.00272.x","article-title":"Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients","volume":"50","author":"Foster","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","article-title":"Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19","volume":"16","author":"Gerber","year":"2004","journal-title":"Chirality"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/alcalc\/agn032","article-title":"Addictions biology: haplotype-based analysis for 130 candidate genes on a single array","volume":"43","author":"Hodgkinson","year":"2008","journal-title":"Alcohol Alcohol"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects","volume":"116","author":"Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/cpt1972136923","article-title":"Disposition of methadone in man after a single oral dose","volume":"13","author":"Inturrisi","year":"1972a","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/cpt1972135part1633","article-title":"The levels of methadone in the plasma in methadone maintenance","volume":"13","author":"Inturrisi","year":"1972b","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2008.104","article-title":"Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance","volume":"84","author":"Kharasch","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","article-title":"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB20|cit20","first-page":"2773","article-title":"Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment","volume":"73","author":"Kreek","year":"1973","journal-title":"N Y State J Med"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB21|cit21","first-page":"451","volume-title":"Handbook of Contemporary Neuropharmacology","author":"Kreek","year":"2007"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrd897","article-title":"Pharmacotherapy of addictions","volume":"1","author":"Kreek","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.103.054866","article-title":"Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression","volume":"307","author":"Lamba","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/hmg\/ddn122","article-title":"ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence","volume":"17","author":"Levran","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03256276","article-title":"Interindividual variability of methadone response: impact of genetic polymorphism","volume":"12","author":"Li","year":"2008","journal-title":"Mol Diagn Ther"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clpt.2005.09.010","article-title":"Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action","volume":"79","author":"Lotsch","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00129785-200404060-00006","article-title":"Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups","volume":"4","author":"Luo","year":"2004","journal-title":"Am J Pharmacogenomics"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"Am J Addict"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB30|cit29","first-page":"406","article-title":"Drug-metabolizing cytochrome P450s in the brain","volume":"27","author":"Miksys","year":"2002","journal-title":"J Psychiatry Neurosci"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB29|cit30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/npp.2008.110","article-title":"Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition","volume":"34","author":"Miksys","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)21130-2","article-title":"Altered methadone pharmacokinetics in methadone-maintained pregnant women","volume":"233","author":"Pond","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2217\/14622416.8.7.721","article-title":"CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population","volume":"8","author":"Scott","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1365-2125.2003.01851.x","article-title":"A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment","volume":"56","author":"Shiran","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2125.2008.03312.x","article-title":"Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment","volume":"67","author":"Shiran","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1124\/dmd.109.027854","article-title":"Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor","volume":"37","author":"Tolson","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism","volume":"108","author":"Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1124\/dmd.31.6.742","article-title":"Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro","volume":"31","author":"Wang","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2217\/14622416.8.7.743","article-title":"Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance","volume":"8","author":"Zanger","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1369-1600.2011.00349.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of human cytochrome P450 enzymes and its clinical impact","volume":"41","author":"Zhou","year":"2009","journal-title":"Drug Metab Rev"}],"container-title":["Addiction Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1369-1600.2011.00349.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1369-1600.2011.00349.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:14:14Z","timestamp":1741353254000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1369-1600.2011.00349.x"}},"subtitle":["CYP2B6 and methadone dose"],"short-title":[],"issued":{"date-parts":[[2011,7,25]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1369-1600.2011.00349.x","relation":{},"ISSN":["1355-6215"],"issn-type":[{"value":"1355-6215","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7,25]]}}}